| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| GATA1 Transcription Factor | 18 | 2022 | 306 | 2.230 |
Why?
|
| Megakaryocytes | 12 | 2019 | 557 | 1.930 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 9 | 2023 | 350 | 1.450 |
Why?
|
| Erythroid Cells | 8 | 2019 | 237 | 1.410 |
Why?
|
| Erythropoiesis | 11 | 2019 | 691 | 1.060 |
Why?
|
| Transcription Factors | 29 | 2020 | 12131 | 1.050 |
Why?
|
| gamma-Globins | 3 | 2022 | 105 | 0.940 |
Why?
|
| DNA-Binding Proteins | 25 | 2020 | 9601 | 0.860 |
Why?
|
| Hemoglobins, Abnormal | 1 | 2022 | 119 | 0.800 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 2022 | 49 | 0.790 |
Why?
|
| Hematopoiesis | 9 | 2021 | 2058 | 0.790 |
Why?
|
| Hemangioblasts | 1 | 2021 | 29 | 0.760 |
Why?
|
| Anemia, Hemolytic | 1 | 2022 | 164 | 0.750 |
Why?
|
| Cell Differentiation | 13 | 2021 | 11641 | 0.750 |
Why?
|
| Core Binding Factor alpha Subunits | 1 | 2020 | 25 | 0.690 |
Why?
|
| Leukemia, Myeloid | 1 | 2022 | 696 | 0.630 |
Why?
|
| Hemolysis | 1 | 2021 | 406 | 0.630 |
Why?
|
| Hematopoietic Stem Cells | 9 | 2021 | 3401 | 0.610 |
Why?
|
| Fanconi Anemia | 1 | 2020 | 327 | 0.560 |
Why?
|
| Erythroid Precursor Cells | 3 | 2011 | 211 | 0.560 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2021 | 328 | 0.550 |
Why?
|
| Gardening | 4 | 2018 | 18 | 0.540 |
Why?
|
| Promoter Regions, Genetic | 5 | 2017 | 5786 | 0.510 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2021 | 587 | 0.500 |
Why?
|
| Neurofibromatosis 1 | 5 | 2020 | 560 | 0.490 |
Why?
|
| src-Family Kinases | 3 | 2015 | 538 | 0.480 |
Why?
|
| Sentinel Lymph Node Biopsy | 11 | 2006 | 728 | 0.480 |
Why?
|
| Nuclear Proteins | 16 | 2012 | 5783 | 0.470 |
Why?
|
| Clostridium Infections | 1 | 2021 | 564 | 0.450 |
Why?
|
| Down Syndrome | 1 | 2022 | 915 | 0.440 |
Why?
|
| Palladium | 5 | 2006 | 67 | 0.430 |
Why?
|
| Embryonic Stem Cells | 6 | 2010 | 1241 | 0.430 |
Why?
|
| Dynamin III | 1 | 2012 | 5 | 0.420 |
Why?
|
| Zinc Fingers | 6 | 2016 | 576 | 0.410 |
Why?
|
| Core Binding Factor beta Subunit | 1 | 2012 | 42 | 0.390 |
Why?
|
| Brachytherapy | 8 | 2006 | 1222 | 0.390 |
Why?
|
| DNA Damage | 3 | 2020 | 2457 | 0.380 |
Why?
|
| Cell Lineage | 5 | 2012 | 2573 | 0.370 |
Why?
|
| Repressor Proteins | 5 | 2012 | 2968 | 0.370 |
Why?
|
| Homeodomain Proteins | 2 | 2012 | 2428 | 0.370 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2012 | 225 | 0.370 |
Why?
|
| GATA2 Transcription Factor | 4 | 2023 | 158 | 0.360 |
Why?
|
| Radioisotopes | 5 | 2006 | 495 | 0.360 |
Why?
|
| Carrier Proteins | 13 | 2015 | 4913 | 0.360 |
Why?
|
| Globins | 1 | 2011 | 406 | 0.350 |
Why?
|
| Erythrocytes | 6 | 2020 | 2395 | 0.350 |
Why?
|
| Thrombopoiesis | 1 | 2012 | 160 | 0.340 |
Why?
|
| Chromatin | 3 | 2012 | 2980 | 0.340 |
Why?
|
| Cell Line | 13 | 2021 | 15543 | 0.330 |
Why?
|
| Blood Platelet Disorders | 2 | 2021 | 59 | 0.330 |
Why?
|
| Erythroid-Specific DNA-Binding Factors | 10 | 2005 | 195 | 0.330 |
Why?
|
| Proto-Oncogene Protein c-fli-1 | 1 | 2009 | 104 | 0.310 |
Why?
|
| Zebrafish Proteins | 4 | 2011 | 1018 | 0.310 |
Why?
|
| Transcriptional Activation | 2 | 2015 | 1744 | 0.300 |
Why?
|
| Gene Expression Regulation, Developmental | 6 | 2019 | 3607 | 0.290 |
Why?
|
| Protein Binding | 10 | 2019 | 9296 | 0.270 |
Why?
|
| Sepsis | 1 | 2021 | 2606 | 0.270 |
Why?
|
| Breast Neoplasms | 26 | 2018 | 21056 | 0.270 |
Why?
|
| Oligosaccharides | 4 | 1992 | 406 | 0.270 |
Why?
|
| Neoplasm Proteins | 5 | 2012 | 3596 | 0.260 |
Why?
|
| Cathepsin D | 4 | 1992 | 59 | 0.260 |
Why?
|
| Angioplasty, Balloon | 2 | 2000 | 608 | 0.250 |
Why?
|
| Humans | 195 | 2023 | 765968 | 0.250 |
Why?
|
| Mice | 38 | 2021 | 81819 | 0.240 |
Why?
|
| Zebrafish | 8 | 2020 | 3036 | 0.240 |
Why?
|
| Genomics | 2 | 2021 | 5929 | 0.240 |
Why?
|
| Animals | 52 | 2021 | 168764 | 0.240 |
Why?
|
| Biotinylation | 3 | 2009 | 184 | 0.230 |
Why?
|
| Transferases (Other Substituted Phosphate Groups) | 3 | 1992 | 34 | 0.230 |
Why?
|
| Blood Platelets | 3 | 2019 | 2464 | 0.230 |
Why?
|
| Prostatic Hyperplasia | 4 | 2012 | 515 | 0.230 |
Why?
|
| Administrative Personnel | 1 | 2005 | 186 | 0.230 |
Why?
|
| Neurofibroma, Plexiform | 2 | 2014 | 66 | 0.220 |
Why?
|
| Heme | 2 | 2017 | 316 | 0.220 |
Why?
|
| Phosphotransferases | 3 | 1992 | 302 | 0.210 |
Why?
|
| Vegetables | 3 | 2018 | 1199 | 0.210 |
Why?
|
| beta-Globins | 2 | 2022 | 112 | 0.210 |
Why?
|
| Lymph Node Excision | 7 | 2006 | 1259 | 0.210 |
Why?
|
| Myocardial Ischemia | 3 | 1998 | 2128 | 0.210 |
Why?
|
| Neoplasm Staging | 33 | 2015 | 11206 | 0.200 |
Why?
|
| Lung Neoplasms | 18 | 2010 | 13451 | 0.200 |
Why?
|
| Genome | 2 | 2011 | 1753 | 0.200 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 19 | 2014 | 11868 | 0.200 |
Why?
|
| Survival Analysis | 23 | 2013 | 10070 | 0.200 |
Why?
|
| Spinal Cord Ischemia | 1 | 2003 | 92 | 0.200 |
Why?
|
| Gene Expression Regulation | 10 | 2020 | 11888 | 0.190 |
Why?
|
| Genome, Human | 2 | 2012 | 4448 | 0.190 |
Why?
|
| Mutation | 15 | 2022 | 30198 | 0.190 |
Why?
|
| Clostridium perfringens | 1 | 2021 | 29 | 0.190 |
Why?
|
| Adenocarcinoma | 9 | 2005 | 6364 | 0.190 |
Why?
|
| Hematologic Diseases | 1 | 2005 | 500 | 0.180 |
Why?
|
| Mast Cells | 2 | 2008 | 1412 | 0.180 |
Why?
|
| Gene Expression Profiling | 9 | 2012 | 9525 | 0.180 |
Why?
|
| Trisomy | 1 | 2022 | 259 | 0.180 |
Why?
|
| Transcription, Genetic | 10 | 2020 | 7599 | 0.180 |
Why?
|
| Research Personnel | 1 | 2005 | 590 | 0.180 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2021 | 3646 | 0.180 |
Why?
|
| Polyethylene Terephthalates | 1 | 2000 | 109 | 0.180 |
Why?
|
| Signal Processing, Computer-Assisted | 2 | 1998 | 1456 | 0.170 |
Why?
|
| Tumor Suppressor Proteins | 6 | 2006 | 2796 | 0.170 |
Why?
|
| Alloys | 1 | 2000 | 111 | 0.170 |
Why?
|
| Electrocardiography | 3 | 1998 | 6404 | 0.170 |
Why?
|
| Lovastatin | 2 | 2019 | 114 | 0.170 |
Why?
|
| Male | 100 | 2022 | 363698 | 0.170 |
Why?
|
| Prostatic Neoplasms | 11 | 2006 | 11083 | 0.170 |
Why?
|
| Middle Aged | 90 | 2021 | 223009 | 0.170 |
Why?
|
| Gene Expression Regulation, Neoplastic | 10 | 2010 | 8611 | 0.170 |
Why?
|
| Sirolimus | 3 | 2020 | 1545 | 0.170 |
Why?
|
| Ultraviolet Rays | 2 | 2015 | 1102 | 0.170 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 10 | 2008 | 5389 | 0.160 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2003 | 1132 | 0.160 |
Why?
|
| cdc42 GTP-Binding Protein | 1 | 2020 | 187 | 0.160 |
Why?
|
| Hypothyroidism | 2 | 2004 | 667 | 0.160 |
Why?
|
| Germ-Line Mutation | 3 | 2023 | 1884 | 0.160 |
Why?
|
| Lymphatic Metastasis | 12 | 2006 | 2887 | 0.160 |
Why?
|
| Clinical Trials as Topic | 3 | 2019 | 8041 | 0.160 |
Why?
|
| Blood Coagulation Disorders, Inherited | 1 | 2019 | 19 | 0.160 |
Why?
|
| Neoadjuvant Therapy | 6 | 2014 | 2895 | 0.160 |
Why?
|
| Leukemia | 2 | 2023 | 1522 | 0.160 |
Why?
|
| Neuroblastoma | 10 | 1997 | 1263 | 0.160 |
Why?
|
| Lysosomes | 3 | 1992 | 932 | 0.150 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2000 | 314 | 0.150 |
Why?
|
| Plant Extracts | 2 | 2012 | 496 | 0.150 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2012 | 4642 | 0.150 |
Why?
|
| Laryngectomy | 1 | 2000 | 244 | 0.150 |
Why?
|
| Molecular Sequence Data | 12 | 2011 | 17594 | 0.150 |
Why?
|
| Aged | 76 | 2021 | 171117 | 0.150 |
Why?
|
| Female | 115 | 2021 | 396112 | 0.150 |
Why?
|
| Phosphorylation | 10 | 2015 | 8278 | 0.150 |
Why?
|
| Endonucleases | 4 | 2010 | 372 | 0.150 |
Why?
|
| Androgen Antagonists | 4 | 2012 | 1411 | 0.150 |
Why?
|
| Ploidies | 4 | 2008 | 287 | 0.150 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2020 | 2056 | 0.150 |
Why?
|
| Primary Myelofibrosis | 1 | 2020 | 210 | 0.150 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2021 | 1560 | 0.150 |
Why?
|
| Aged, 80 and over | 43 | 2018 | 59489 | 0.140 |
Why?
|
| Carcinoma, Ductal, Breast | 8 | 2014 | 1083 | 0.140 |
Why?
|
| Heterozygote | 2 | 2022 | 2794 | 0.140 |
Why?
|
| Cell Adhesion | 2 | 2021 | 3089 | 0.140 |
Why?
|
| Renal Agents | 1 | 1997 | 30 | 0.140 |
Why?
|
| Proto-Oncogene Proteins | 6 | 2015 | 4520 | 0.140 |
Why?
|
| Exercise | 4 | 2018 | 5937 | 0.140 |
Why?
|
| Signal Transduction | 9 | 2017 | 23601 | 0.140 |
Why?
|
| Enuresis | 1 | 1997 | 45 | 0.140 |
Why?
|
| Chromatography, Affinity | 4 | 2012 | 521 | 0.140 |
Why?
|
| Burnout, Professional | 1 | 2005 | 711 | 0.140 |
Why?
|
| A Kinase Anchor Proteins | 1 | 2017 | 57 | 0.140 |
Why?
|
| Adult | 81 | 2021 | 223044 | 0.140 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 1997 | 87 | 0.130 |
Why?
|
| Laryngeal Neoplasms | 1 | 2000 | 512 | 0.130 |
Why?
|
| Cytokines | 1 | 2012 | 7421 | 0.130 |
Why?
|
| Antineoplastic Agents | 13 | 2020 | 13648 | 0.130 |
Why?
|
| Mice, Knockout | 8 | 2019 | 14448 | 0.130 |
Why?
|
| Translocation, Genetic | 1 | 2002 | 1394 | 0.130 |
Why?
|
| Angioplasty | 1 | 1999 | 352 | 0.130 |
Why?
|
| Employment | 1 | 2002 | 1106 | 0.130 |
Why?
|
| Multiprotein Complexes | 2 | 2015 | 1107 | 0.130 |
Why?
|
| Carcinoma, Lobular | 6 | 2014 | 471 | 0.130 |
Why?
|
| Neoplasms | 13 | 2021 | 22340 | 0.130 |
Why?
|
| Neoplasm Invasiveness | 6 | 2014 | 3602 | 0.130 |
Why?
|
| Enzyme Precursors | 2 | 1992 | 164 | 0.130 |
Why?
|
| Cyclins | 3 | 2003 | 598 | 0.130 |
Why?
|
| Infant, Newborn | 9 | 2022 | 26346 | 0.130 |
Why?
|
| Prostate-Specific Antigen | 6 | 2012 | 2464 | 0.130 |
Why?
|
| Mannose | 2 | 1992 | 119 | 0.120 |
Why?
|
| Cell Line, Tumor | 8 | 2021 | 17075 | 0.120 |
Why?
|
| STAT3 Transcription Factor | 5 | 2006 | 870 | 0.120 |
Why?
|
| Graft Occlusion, Vascular | 1 | 1999 | 540 | 0.120 |
Why?
|
| Protein Interaction Mapping | 2 | 2009 | 619 | 0.120 |
Why?
|
| Urine | 1 | 1997 | 360 | 0.120 |
Why?
|
| Binding Sites | 7 | 2011 | 6001 | 0.120 |
Why?
|
| Eukaryotic Initiation Factors | 1 | 2015 | 83 | 0.120 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2016 | 280 | 0.120 |
Why?
|
| Survival Rate | 23 | 2014 | 12795 | 0.120 |
Why?
|
| Leg | 2 | 1999 | 1080 | 0.120 |
Why?
|
| Florida | 9 | 2016 | 416 | 0.120 |
Why?
|
| Trans-Activators | 5 | 2005 | 2850 | 0.110 |
Why?
|
| Prognosis | 37 | 2014 | 29922 | 0.110 |
Why?
|
| Phenotype | 4 | 2022 | 16721 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2021 | 16047 | 0.110 |
Why?
|
| Pregnancy Complications, Hematologic | 2 | 2016 | 183 | 0.110 |
Why?
|
| Ergometry | 1 | 1993 | 17 | 0.110 |
Why?
|
| Sunbathing | 1 | 2014 | 66 | 0.110 |
Why?
|
| Predictive Value of Tests | 18 | 2015 | 15398 | 0.110 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2021 | 1657 | 0.110 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2001 | 920 | 0.110 |
Why?
|
| Erythropoietin | 2 | 2017 | 716 | 0.110 |
Why?
|
| Thallium Radioisotopes | 3 | 1998 | 135 | 0.110 |
Why?
|
| Cancer Vaccines | 3 | 2008 | 1044 | 0.110 |
Why?
|
| Granulocytes | 1 | 2015 | 549 | 0.110 |
Why?
|
| Income | 1 | 2002 | 1874 | 0.110 |
Why?
|
| Fatty Acids | 1 | 2001 | 1806 | 0.110 |
Why?
|
| Leucine | 1 | 2015 | 546 | 0.110 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2021 | 2900 | 0.110 |
Why?
|
| Radiometry | 2 | 2011 | 804 | 0.110 |
Why?
|
| Cosmetics | 1 | 2014 | 102 | 0.110 |
Why?
|
| Glioblastoma | 3 | 2014 | 3459 | 0.110 |
Why?
|
| Thrombocytopenia | 1 | 2021 | 1171 | 0.110 |
Why?
|
| Histone Deacetylases | 2 | 2015 | 708 | 0.110 |
Why?
|
| Verapamil | 1 | 1993 | 242 | 0.100 |
Why?
|
| Genes, BRCA2 | 2 | 2007 | 588 | 0.100 |
Why?
|
| Aging | 4 | 2001 | 8731 | 0.100 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 1 | 2014 | 169 | 0.100 |
Why?
|
| Melanoma | 7 | 2015 | 5719 | 0.100 |
Why?
|
| Postpartum Hemorrhage | 1 | 2016 | 276 | 0.100 |
Why?
|
| Perfusion Imaging | 1 | 2014 | 193 | 0.100 |
Why?
|
| Chromatin Immunoprecipitation | 3 | 2011 | 857 | 0.100 |
Why?
|
| Streptavidin | 2 | 2009 | 81 | 0.100 |
Why?
|
| Electron Transport Complex IV | 1 | 2013 | 188 | 0.100 |
Why?
|
| Stillbirth | 1 | 2016 | 381 | 0.100 |
Why?
|
| Mice, Transgenic | 8 | 2012 | 9550 | 0.100 |
Why?
|
| Smoking Cessation | 1 | 2004 | 2084 | 0.100 |
Why?
|
| DNA | 5 | 2015 | 7202 | 0.100 |
Why?
|
| Asparagine | 1 | 1992 | 120 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 10 | 2015 | 22332 | 0.100 |
Why?
|
| Cost of Illness | 1 | 2002 | 1950 | 0.100 |
Why?
|
| Glioma | 2 | 2020 | 3493 | 0.100 |
Why?
|
| DNA Topoisomerases, Type II | 2 | 2010 | 122 | 0.100 |
Why?
|
| K562 Cells | 2 | 2011 | 649 | 0.100 |
Why?
|
| Child, Preschool | 19 | 2022 | 42500 | 0.100 |
Why?
|
| Live Birth | 1 | 2016 | 516 | 0.100 |
Why?
|
| Fruit | 1 | 2018 | 1166 | 0.100 |
Why?
|
| Chemokines | 1 | 2016 | 956 | 0.100 |
Why?
|
| Disease-Free Survival | 10 | 2014 | 6832 | 0.100 |
Why?
|
| Prostatectomy | 3 | 2005 | 1782 | 0.100 |
Why?
|
| Tritium | 1 | 1992 | 702 | 0.100 |
Why?
|
| Soft Tissue Neoplasms | 3 | 2014 | 1165 | 0.100 |
Why?
|
| Cell Membrane | 1 | 2001 | 3634 | 0.100 |
Why?
|
| Radiation Tolerance | 2 | 2005 | 475 | 0.100 |
Why?
|
| Hemoglobins | 2 | 2015 | 1530 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 4 | 2007 | 372 | 0.100 |
Why?
|
| Protein Structure, Tertiary | 3 | 2004 | 3750 | 0.100 |
Why?
|
| Plant Preparations | 1 | 2012 | 93 | 0.100 |
Why?
|
| Sialoglycoproteins | 2 | 2003 | 313 | 0.100 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2016 | 245 | 0.090 |
Why?
|
| Hematologic Neoplasms | 1 | 2023 | 1927 | 0.090 |
Why?
|
| Ribosomes | 1 | 2015 | 493 | 0.090 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 2 | 2009 | 792 | 0.090 |
Why?
|
| Gene Knockdown Techniques | 2 | 2016 | 1599 | 0.090 |
Why?
|
| Home Care Services | 1 | 2018 | 660 | 0.090 |
Why?
|
| Mastectomy | 3 | 2014 | 1847 | 0.090 |
Why?
|
| Magnetic Field Therapy | 1 | 2011 | 27 | 0.090 |
Why?
|
| Cytoskeleton | 1 | 2016 | 1178 | 0.090 |
Why?
|
| Base Sequence | 8 | 2013 | 12403 | 0.090 |
Why?
|
| Urination | 1 | 2012 | 204 | 0.090 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 2007 | 540 | 0.090 |
Why?
|
| Glycoproteins | 2 | 2004 | 2195 | 0.090 |
Why?
|
| Infant | 18 | 2022 | 36386 | 0.090 |
Why?
|
| Congenital Abnormalities | 1 | 2016 | 704 | 0.090 |
Why?
|
| T-Lymphocytes | 5 | 2016 | 10261 | 0.090 |
Why?
|
| Phosphoproteins | 2 | 2015 | 2446 | 0.090 |
Why?
|
| Isotope Labeling | 1 | 1992 | 389 | 0.090 |
Why?
|
| Combined Modality Therapy | 13 | 2014 | 8529 | 0.090 |
Why?
|
| Head and Neck Neoplasms | 3 | 2005 | 2921 | 0.090 |
Why?
|
| Interdisciplinary Communication | 1 | 2016 | 932 | 0.090 |
Why?
|
| Smoking | 2 | 2004 | 9081 | 0.090 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2011 | 88 | 0.090 |
Why?
|
| Retrospective Studies | 34 | 2016 | 81514 | 0.090 |
Why?
|
| Etoposide | 3 | 2010 | 636 | 0.090 |
Why?
|
| Urinary Bladder | 1 | 1997 | 1154 | 0.090 |
Why?
|
| Brain Neoplasms | 5 | 2014 | 9071 | 0.090 |
Why?
|
| Models, Biological | 4 | 2011 | 9443 | 0.090 |
Why?
|
| Phytotherapy | 1 | 2012 | 298 | 0.090 |
Why?
|
| Community Health Centers | 2 | 2004 | 469 | 0.090 |
Why?
|
| Genital Neoplasms, Female | 2 | 2006 | 533 | 0.090 |
Why?
|
| Urination Disorders | 1 | 2011 | 236 | 0.090 |
Why?
|
| Interleukin-2 | 3 | 2008 | 1896 | 0.090 |
Why?
|
| Deoxycytidine | 4 | 2010 | 889 | 0.090 |
Why?
|
| Research Design | 4 | 2016 | 6209 | 0.090 |
Why?
|
| Liver Neoplasms | 5 | 2011 | 4353 | 0.080 |
Why?
|
| Biomedical Research | 1 | 2005 | 3458 | 0.080 |
Why?
|
| Cells, Cultured | 5 | 2015 | 18973 | 0.080 |
Why?
|
| Wound Healing | 1 | 2000 | 2792 | 0.080 |
Why?
|
| Radiopharmaceuticals | 2 | 2002 | 2699 | 0.080 |
Why?
|
| Sensitivity and Specificity | 12 | 2015 | 14652 | 0.080 |
Why?
|
| Embryo, Nonmammalian | 2 | 2015 | 907 | 0.080 |
Why?
|
| Sequence Deletion | 3 | 2002 | 1495 | 0.080 |
Why?
|
| Adolescent | 31 | 2021 | 88835 | 0.080 |
Why?
|
| Skin Neoplasms | 5 | 2015 | 5849 | 0.080 |
Why?
|
| Amino Acid Sequence | 7 | 2008 | 13400 | 0.080 |
Why?
|
| Child | 28 | 2021 | 80564 | 0.080 |
Why?
|
| Flutamide | 2 | 2000 | 96 | 0.080 |
Why?
|
| Neoplasm Metastasis | 5 | 2011 | 4893 | 0.080 |
Why?
|
| Hodgkin Disease | 5 | 1997 | 1383 | 0.080 |
Why?
|
| Stents | 1 | 2000 | 3213 | 0.080 |
Why?
|
| Valproic Acid | 1 | 2011 | 445 | 0.080 |
Why?
|
| Biotin | 1 | 2009 | 257 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2008 | 4044 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2012 | 10729 | 0.080 |
Why?
|
| Germ Cells | 2 | 2023 | 647 | 0.080 |
Why?
|
| Disease Progression | 8 | 2019 | 13632 | 0.080 |
Why?
|
| Immunohistochemistry | 11 | 2013 | 11022 | 0.080 |
Why?
|
| Microarray Analysis | 1 | 2011 | 752 | 0.080 |
Why?
|
| Methods | 1 | 2008 | 1052 | 0.080 |
Why?
|
| Herpesvirus 1, Human | 1 | 2014 | 743 | 0.080 |
Why?
|
| Carcinoma, Small Cell | 1 | 2010 | 420 | 0.070 |
Why?
|
| Single Person | 1 | 1988 | 31 | 0.070 |
Why?
|
| Radionuclide Imaging | 5 | 2002 | 1978 | 0.070 |
Why?
|
| Hepatic Artery | 2 | 2006 | 231 | 0.070 |
Why?
|
| Carbohydrate Sequence | 3 | 1992 | 410 | 0.070 |
Why?
|
| Spinal Neoplasms | 1 | 2014 | 708 | 0.070 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2009 | 822 | 0.070 |
Why?
|
| Gamma Rays | 2 | 2007 | 324 | 0.070 |
Why?
|
| Yolk Sac | 1 | 2008 | 79 | 0.070 |
Why?
|
| Executive Function | 1 | 2016 | 1391 | 0.070 |
Why?
|
| Animals, Genetically Modified | 2 | 2015 | 1560 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2014 | 36532 | 0.070 |
Why?
|
| Follow-Up Studies | 11 | 2014 | 39193 | 0.070 |
Why?
|
| Antigens, Neoplasm | 2 | 2010 | 2002 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 2 | 2003 | 2686 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 2 | 2006 | 9249 | 0.070 |
Why?
|
| Diet | 2 | 2018 | 8086 | 0.070 |
Why?
|
| Antineoplastic Agents, Phytogenic | 3 | 2010 | 616 | 0.070 |
Why?
|
| Leuprolide | 2 | 2000 | 312 | 0.070 |
Why?
|
| Vinblastine | 3 | 2005 | 483 | 0.070 |
Why?
|
| Biopsy | 7 | 2015 | 6763 | 0.070 |
Why?
|
| Treatment Outcome | 23 | 2014 | 65188 | 0.070 |
Why?
|
| Cell Culture Techniques | 2 | 2012 | 1652 | 0.070 |
Why?
|
| Uncertainty | 2 | 2003 | 761 | 0.070 |
Why?
|
| Mice, Mutant Strains | 2 | 2008 | 1745 | 0.070 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2012 | 722 | 0.070 |
Why?
|
| Probability | 6 | 2005 | 2475 | 0.070 |
Why?
|
| Paget's Disease, Mammary | 1 | 2006 | 18 | 0.070 |
Why?
|
| Camptothecin | 2 | 2010 | 600 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2015 | 4562 | 0.070 |
Why?
|
| Reproducibility of Results | 5 | 2019 | 20124 | 0.070 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2009 | 1724 | 0.070 |
Why?
|
| Protein Multimerization | 1 | 2012 | 959 | 0.070 |
Why?
|
| Adenoma | 3 | 2004 | 2152 | 0.070 |
Why?
|
| Multipotent Stem Cells | 1 | 2008 | 199 | 0.070 |
Why?
|
| Genes, myc | 4 | 1997 | 393 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 9 | 2008 | 6113 | 0.060 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2007 | 306 | 0.060 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2009 | 657 | 0.060 |
Why?
|
| Prospective Studies | 22 | 2015 | 54802 | 0.060 |
Why?
|
| Abdominal Cavity | 1 | 2006 | 33 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 1 | 3 | 1995 | 3446 | 0.060 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2010 | 647 | 0.060 |
Why?
|
| Genotype | 2 | 2019 | 13024 | 0.060 |
Why?
|
| Fetal Hemoglobin | 1 | 2008 | 348 | 0.060 |
Why?
|
| Colonic Neoplasms | 3 | 2003 | 2531 | 0.060 |
Why?
|
| Logistic Models | 7 | 2005 | 13266 | 0.060 |
Why?
|
| Exercise Test | 3 | 1998 | 2180 | 0.060 |
Why?
|
| Transduction, Genetic | 1 | 2008 | 898 | 0.060 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2006 | 891 | 0.060 |
Why?
|
| Feasibility Studies | 4 | 2018 | 5302 | 0.060 |
Why?
|
| Gene Transfer Techniques | 1 | 2011 | 1216 | 0.060 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2006 | 158 | 0.060 |
Why?
|
| HEK293 Cells | 3 | 2021 | 4260 | 0.060 |
Why?
|
| Genes, BRCA1 | 2 | 2007 | 750 | 0.060 |
Why?
|
| Serine | 1 | 2009 | 824 | 0.060 |
Why?
|
| Cerebral Cortex | 1 | 2001 | 5767 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 6 | 2013 | 6069 | 0.060 |
Why?
|
| Keratins | 3 | 2002 | 498 | 0.060 |
Why?
|
| Membrane Transport Proteins | 1 | 2011 | 1028 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2010 | 995 | 0.060 |
Why?
|
| Quality of Life | 8 | 2018 | 13462 | 0.060 |
Why?
|
| Cluster Analysis | 1 | 2012 | 2721 | 0.060 |
Why?
|
| Pilot Projects | 7 | 2018 | 8733 | 0.060 |
Why?
|
| Apoptosis | 8 | 2007 | 9514 | 0.060 |
Why?
|
| CD40 Ligand | 1 | 2006 | 528 | 0.060 |
Why?
|
| Iodine Radioisotopes | 3 | 2006 | 1029 | 0.060 |
Why?
|
| Family | 1 | 1995 | 3209 | 0.060 |
Why?
|
| Health Behavior | 3 | 2018 | 2650 | 0.060 |
Why?
|
| Mitochondrial Membranes | 2 | 2017 | 184 | 0.060 |
Why?
|
| Ovarian Neoplasms | 3 | 2007 | 4900 | 0.060 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2006 | 249 | 0.060 |
Why?
|
| Gene Expression | 5 | 2015 | 7584 | 0.060 |
Why?
|
| Embryonic Development | 1 | 2009 | 718 | 0.060 |
Why?
|
| Urinary Reservoirs, Continent | 1 | 2004 | 29 | 0.060 |
Why?
|
| Carcinoid Tumor | 1 | 2006 | 225 | 0.060 |
Why?
|
| Colorectal Neoplasms | 4 | 2006 | 6942 | 0.060 |
Why?
|
| Ganglioneuroma | 3 | 1993 | 53 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2014 | 9373 | 0.050 |
Why?
|
| Premature Birth | 1 | 2016 | 1829 | 0.050 |
Why?
|
| Somatostatin | 1 | 2006 | 459 | 0.050 |
Why?
|
| Forms and Records Control | 1 | 2004 | 158 | 0.050 |
Why?
|
| Premenopause | 2 | 2005 | 1037 | 0.050 |
Why?
|
| Alkyl and Aryl Transferases | 1 | 2004 | 89 | 0.050 |
Why?
|
| Carcinoma in Situ | 2 | 2007 | 779 | 0.050 |
Why?
|
| Surgicenters | 1 | 2003 | 38 | 0.050 |
Why?
|
| Acute-Phase Reaction | 1 | 2003 | 90 | 0.050 |
Why?
|
| Isoflavones | 1 | 2004 | 139 | 0.050 |
Why?
|
| Physicians' Offices | 1 | 2003 | 60 | 0.050 |
Why?
|
| Bone Marrow Cells | 2 | 2008 | 2412 | 0.050 |
Why?
|
| Gene Silencing | 1 | 2009 | 1505 | 0.050 |
Why?
|
| Axilla | 5 | 2006 | 615 | 0.050 |
Why?
|
| Tretinoin | 1 | 2006 | 524 | 0.050 |
Why?
|
| Precancerous Conditions | 2 | 2007 | 976 | 0.050 |
Why?
|
| Genes, cdc | 1 | 2003 | 113 | 0.050 |
Why?
|
| Ki-67 Antigen | 4 | 2007 | 629 | 0.050 |
Why?
|
| Age Distribution | 2 | 2005 | 2858 | 0.050 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2003 | 112 | 0.050 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2006 | 287 | 0.050 |
Why?
|
| Tryptophan Oxygenase | 1 | 2002 | 19 | 0.050 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2005 | 416 | 0.050 |
Why?
|
| Paraplegia | 1 | 2003 | 158 | 0.050 |
Why?
|
| Carbohydrate Conformation | 2 | 1992 | 206 | 0.050 |
Why?
|
| Triterpenes | 1 | 2003 | 78 | 0.050 |
Why?
|
| Serenoa | 2 | 2012 | 11 | 0.050 |
Why?
|
| Lymph Nodes | 4 | 2002 | 3454 | 0.050 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2012 | 1892 | 0.050 |
Why?
|
| Mouth Mucosa | 2 | 2011 | 432 | 0.050 |
Why?
|
| Carboplatin | 4 | 2010 | 789 | 0.050 |
Why?
|
| Survivors | 1 | 2013 | 2372 | 0.050 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2011 | 2329 | 0.050 |
Why?
|
| Plasmids | 3 | 2009 | 2274 | 0.050 |
Why?
|
| Sphingosine | 1 | 2004 | 306 | 0.050 |
Why?
|
| Doxorubicin | 8 | 2006 | 2230 | 0.050 |
Why?
|
| Survival | 1 | 2002 | 160 | 0.050 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein Group A-B | 1 | 2001 | 30 | 0.050 |
Why?
|
| Ureteral Obstruction | 1 | 2004 | 291 | 0.050 |
Why?
|
| Pulmonary Embolism | 2 | 2006 | 2598 | 0.050 |
Why?
|
| Postoperative Complications | 2 | 2004 | 15747 | 0.050 |
Why?
|
| Genistein | 1 | 2002 | 87 | 0.050 |
Why?
|
| Personality | 1 | 2005 | 560 | 0.050 |
Why?
|
| Medical Records | 2 | 2004 | 1409 | 0.050 |
Why?
|
| Lysophospholipids | 1 | 2004 | 335 | 0.050 |
Why?
|
| Gene Regulatory Networks | 1 | 2010 | 1748 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 4058 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2005 | 10383 | 0.050 |
Why?
|
| DNA, Complementary | 1 | 2005 | 1984 | 0.050 |
Why?
|
| Patient Satisfaction | 3 | 2018 | 3475 | 0.050 |
Why?
|
| Genetic Markers | 2 | 2005 | 2601 | 0.050 |
Why?
|
| Job Satisfaction | 1 | 2005 | 549 | 0.050 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2007 | 2844 | 0.050 |
Why?
|
| Genetic Loci | 1 | 2011 | 2631 | 0.050 |
Why?
|
| Risk Factors | 13 | 2006 | 74840 | 0.050 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2003 | 507 | 0.050 |
Why?
|
| Ribonucleoside Diphosphate Reductase | 3 | 2006 | 31 | 0.050 |
Why?
|
| Quality Improvement | 1 | 2016 | 3853 | 0.050 |
Why?
|
| Double-Blind Method | 4 | 2019 | 12437 | 0.050 |
Why?
|
| Adjuvants, Immunologic | 1 | 2006 | 995 | 0.050 |
Why?
|
| Receptors, Estrogen | 4 | 2013 | 2242 | 0.050 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2005 | 705 | 0.050 |
Why?
|
| Anemia | 2 | 2014 | 1511 | 0.050 |
Why?
|
| Cloning, Molecular | 4 | 1999 | 4165 | 0.050 |
Why?
|
| Amphotericin B | 2 | 2002 | 140 | 0.050 |
Why?
|
| Proportional Hazards Models | 5 | 2010 | 12509 | 0.050 |
Why?
|
| Radiotherapy Dosage | 2 | 1998 | 2865 | 0.050 |
Why?
|
| Estrone | 1 | 2002 | 234 | 0.050 |
Why?
|
| Mitochondria | 1 | 2014 | 3673 | 0.050 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2002 | 176 | 0.050 |
Why?
|
| Chromosome Breakage | 1 | 2021 | 159 | 0.040 |
Why?
|
| Cell Cycle Proteins | 3 | 2015 | 3430 | 0.040 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2000 | 1534 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2011 | 3715 | 0.040 |
Why?
|
| Response Elements | 1 | 2002 | 307 | 0.040 |
Why?
|
| Oncogene Protein p21(ras) | 1 | 2000 | 68 | 0.040 |
Why?
|
| Vaccines, DNA | 1 | 2002 | 279 | 0.040 |
Why?
|
| Quinazolines | 2 | 2005 | 1364 | 0.040 |
Why?
|
| Smad1 Protein | 1 | 2020 | 81 | 0.040 |
Why?
|
| Fibromuscular Dysplasia | 1 | 2000 | 56 | 0.040 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2006 | 1066 | 0.040 |
Why?
|
| Epidermal Growth Factor | 1 | 2003 | 698 | 0.040 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2023 | 384 | 0.040 |
Why?
|
| Mass Screening | 4 | 2004 | 5446 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2005 | 2263 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 2 | 2004 | 5526 | 0.040 |
Why?
|
| Pain Measurement | 2 | 2014 | 3561 | 0.040 |
Why?
|
| Tryptophan | 1 | 2002 | 483 | 0.040 |
Why?
|
| Multivariate Analysis | 5 | 2005 | 12056 | 0.040 |
Why?
|
| Regression Analysis | 3 | 2001 | 6322 | 0.040 |
Why?
|
| Quinolones | 1 | 2004 | 387 | 0.040 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2004 | 326 | 0.040 |
Why?
|
| Mitotic Index | 2 | 2000 | 159 | 0.040 |
Why?
|
| Aneurysm | 1 | 2003 | 337 | 0.040 |
Why?
|
| Anticarcinogenic Agents | 1 | 2002 | 250 | 0.040 |
Why?
|
| Family Relations | 1 | 2002 | 318 | 0.040 |
Why?
|
| Liver | 3 | 2014 | 7562 | 0.040 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2008 | 3181 | 0.040 |
Why?
|
| Research Support as Topic | 2 | 2003 | 696 | 0.040 |
Why?
|
| Cell Division | 6 | 2003 | 4475 | 0.040 |
Why?
|
| Enhancer Elements, Genetic | 2 | 2020 | 1365 | 0.040 |
Why?
|
| Phosphotyrosine | 2 | 2015 | 459 | 0.040 |
Why?
|
| Protein Isoforms | 2 | 2019 | 1718 | 0.040 |
Why?
|
| Retroviridae | 1 | 2002 | 847 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2004 | 3230 | 0.040 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2000 | 122 | 0.040 |
Why?
|
| Urinary Incontinence | 1 | 2004 | 491 | 0.040 |
Why?
|
| Models, Genetic | 1 | 2009 | 3449 | 0.040 |
Why?
|
| Image Cytometry | 1 | 1999 | 51 | 0.040 |
Why?
|
| Multiple Myeloma | 3 | 2004 | 5197 | 0.040 |
Why?
|
| Microsatellite Repeats | 1 | 2001 | 784 | 0.040 |
Why?
|
| Phylogeny | 2 | 2004 | 2832 | 0.040 |
Why?
|
| Oocytes | 3 | 1992 | 1169 | 0.040 |
Why?
|
| Neuroendocrine Tumors | 1 | 2006 | 654 | 0.040 |
Why?
|
| Candidiasis | 1 | 2002 | 371 | 0.040 |
Why?
|
| Emotions | 2 | 2014 | 2763 | 0.040 |
Why?
|
| Aortography | 1 | 2000 | 414 | 0.040 |
Why?
|
| Algorithms | 7 | 2011 | 14071 | 0.040 |
Why?
|
| Radiation Oncology | 1 | 2005 | 569 | 0.040 |
Why?
|
| Endometrial Hyperplasia | 1 | 1999 | 101 | 0.040 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2003 | 453 | 0.040 |
Why?
|
| Life Tables | 1 | 1999 | 363 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 1 | 2009 | 4772 | 0.040 |
Why?
|
| Xenopus laevis | 2 | 1992 | 964 | 0.040 |
Why?
|
| Kidney Neoplasms | 2 | 2008 | 4274 | 0.040 |
Why?
|
| Menstrual Cycle | 1 | 2002 | 540 | 0.040 |
Why?
|
| DNA Topoisomerases, Type I | 2 | 2010 | 108 | 0.040 |
Why?
|
| Chromosome Disorders | 1 | 2021 | 498 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2006 | 639 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2002 | 1061 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 4 | 2005 | 3537 | 0.040 |
Why?
|
| Estradiol | 2 | 2004 | 1947 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2004 | 1472 | 0.040 |
Why?
|
| Mastectomy, Segmental | 2 | 2001 | 964 | 0.040 |
Why?
|
| Body Composition | 2 | 2005 | 2439 | 0.040 |
Why?
|
| Social Desirability | 1 | 2018 | 45 | 0.040 |
Why?
|
| Cell Nucleus | 1 | 2007 | 2867 | 0.040 |
Why?
|
| Age Factors | 9 | 2005 | 18380 | 0.040 |
Why?
|
| Genes, ras | 1 | 2000 | 658 | 0.040 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 1999 | 208 | 0.040 |
Why?
|
| Alabama | 1 | 2018 | 111 | 0.040 |
Why?
|
| Aorta, Abdominal | 1 | 2000 | 596 | 0.040 |
Why?
|
| Sexual Behavior | 1 | 1988 | 2193 | 0.040 |
Why?
|
| Restriction Mapping | 3 | 1992 | 848 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2014 | 5696 | 0.040 |
Why?
|
| Radiotherapy | 2 | 2010 | 1494 | 0.040 |
Why?
|
| Intestinal Neoplasms | 1 | 2000 | 313 | 0.040 |
Why?
|
| Pedigree | 2 | 2021 | 4526 | 0.040 |
Why?
|
| Random Allocation | 2 | 2003 | 2395 | 0.040 |
Why?
|
| Computational Biology | 1 | 2009 | 3559 | 0.040 |
Why?
|
| Ifosfamide | 2 | 1995 | 233 | 0.040 |
Why?
|
| Neoplasms, Experimental | 1 | 2002 | 1229 | 0.040 |
Why?
|
| Islets of Langerhans | 2 | 1995 | 1349 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2010 | 5337 | 0.040 |
Why?
|
| Young Adult | 8 | 2019 | 59889 | 0.030 |
Why?
|
| Receptors, Progesterone | 2 | 2013 | 1153 | 0.030 |
Why?
|
| Eosinophils | 1 | 2002 | 945 | 0.030 |
Why?
|
| Sickness Impact Profile | 1 | 1998 | 297 | 0.030 |
Why?
|
| Rabbits | 1 | 2003 | 4734 | 0.030 |
Why?
|
| Lymphatic Irradiation | 1 | 1997 | 110 | 0.030 |
Why?
|
| Vincristine | 5 | 2000 | 1039 | 0.030 |
Why?
|
| Staining and Labeling | 1 | 2001 | 1072 | 0.030 |
Why?
|
| Blood Flow Velocity | 1 | 2000 | 1381 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 1998 | 11499 | 0.030 |
Why?
|
| False Negative Reactions | 3 | 2002 | 573 | 0.030 |
Why?
|
| Perinatology | 1 | 2016 | 64 | 0.030 |
Why?
|
| Time Factors | 5 | 2011 | 40065 | 0.030 |
Why?
|
| Enzyme Activation | 2 | 2016 | 3586 | 0.030 |
Why?
|
| Confidence Intervals | 2 | 2005 | 2910 | 0.030 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 1997 | 587 | 0.030 |
Why?
|
| Embolization, Therapeutic | 1 | 2006 | 1403 | 0.030 |
Why?
|
| Observer Variation | 2 | 2000 | 2615 | 0.030 |
Why?
|
| Siblings | 1 | 2020 | 828 | 0.030 |
Why?
|
| Chromatography, Ion Exchange | 2 | 1992 | 289 | 0.030 |
Why?
|
| Osmolar Concentration | 1 | 1997 | 655 | 0.030 |
Why?
|
| Dogs | 1 | 2000 | 3822 | 0.030 |
Why?
|
| Sarcoma | 2 | 1998 | 1802 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2003 | 2666 | 0.030 |
Why?
|
| Health Surveys | 1 | 2005 | 4056 | 0.030 |
Why?
|
| Receptor, erbB-2 | 3 | 2013 | 2593 | 0.030 |
Why?
|
| Vascular Patency | 1 | 1999 | 912 | 0.030 |
Why?
|
| Amino Acid Transport Systems, Basic | 1 | 2015 | 35 | 0.030 |
Why?
|
| Insulin Antibodies | 1 | 1995 | 28 | 0.030 |
Why?
|
| Analysis of Variance | 3 | 2013 | 6203 | 0.030 |
Why?
|
| Spinal Cord | 1 | 2003 | 1784 | 0.030 |
Why?
|
| Cell Shape | 1 | 2016 | 373 | 0.030 |
Why?
|
| Proteomics | 1 | 2009 | 3910 | 0.030 |
Why?
|
| Aspergillosis | 1 | 1997 | 242 | 0.030 |
Why?
|
| Treatment Failure | 2 | 1999 | 2652 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2021 | 3067 | 0.030 |
Why?
|
| Administration, Intranasal | 1 | 1997 | 482 | 0.030 |
Why?
|
| Jurkat Cells | 1 | 2016 | 737 | 0.030 |
Why?
|
| DNA Primers | 2 | 2013 | 2825 | 0.030 |
Why?
|
| Protein Conformation | 2 | 1992 | 3946 | 0.030 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2017 | 484 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2011 | 869 | 0.030 |
Why?
|
| Placebos | 3 | 2004 | 1659 | 0.030 |
Why?
|
| Fluorouracil | 3 | 2010 | 1648 | 0.030 |
Why?
|
| Weight Gain | 3 | 2004 | 2355 | 0.030 |
Why?
|
| Urinalysis | 1 | 1997 | 368 | 0.030 |
Why?
|
| Transfection | 4 | 2008 | 5743 | 0.030 |
Why?
|
| Veins | 1 | 1999 | 764 | 0.030 |
Why?
|
| Personnel, Hospital | 1 | 2016 | 286 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 3 | 2003 | 1600 | 0.030 |
Why?
|
| Glycopeptides | 2 | 1992 | 224 | 0.030 |
Why?
|
| Gene Amplification | 3 | 1997 | 1091 | 0.030 |
Why?
|
| Spleen | 1 | 2020 | 2296 | 0.030 |
Why?
|
| Fetal Death | 1 | 2016 | 435 | 0.030 |
Why?
|
| Protoporphyrins | 1 | 2014 | 167 | 0.030 |
Why?
|
| B-Lymphocytes | 2 | 2021 | 4778 | 0.030 |
Why?
|
| Waist Circumference | 1 | 2018 | 932 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 1996 | 755 | 0.030 |
Why?
|
| Protein Stability | 1 | 2015 | 577 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2003 | 2423 | 0.030 |
Why?
|
| Diagnostic Errors | 1 | 2001 | 1275 | 0.030 |
Why?
|
| Sex Factors | 3 | 2004 | 10603 | 0.030 |
Why?
|
| Xenopus | 2 | 1992 | 709 | 0.030 |
Why?
|
| RNA Interference | 2 | 2015 | 2832 | 0.030 |
Why?
|
| Health Plan Implementation | 1 | 2016 | 338 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2006 | 1410 | 0.030 |
Why?
|
| Carcinoma | 1 | 2005 | 2312 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 2 | 2006 | 898 | 0.030 |
Why?
|
| Hypertension | 1 | 1993 | 8626 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2004 | 2942 | 0.030 |
Why?
|
| Perfusion | 1 | 1998 | 1407 | 0.030 |
Why?
|
| Isometric Contraction | 1 | 1993 | 149 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2009 | 3797 | 0.030 |
Why?
|
| Lymphocytes | 1 | 2001 | 2599 | 0.030 |
Why?
|
| Pepsinogens | 1 | 1992 | 7 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2020 | 18071 | 0.030 |
Why?
|
| Occult Blood | 2 | 2004 | 198 | 0.030 |
Why?
|
| Papillomavirus Infections | 1 | 2005 | 1640 | 0.030 |
Why?
|
| Organoplatinum Compounds | 2 | 2010 | 404 | 0.030 |
Why?
|
| General Surgery | 2 | 2001 | 1722 | 0.030 |
Why?
|
| Extremities | 1 | 1998 | 869 | 0.030 |
Why?
|
| Disabled Persons | 1 | 2002 | 1208 | 0.030 |
Why?
|
| Ribosomal Proteins | 1 | 2015 | 366 | 0.030 |
Why?
|
| Tamoxifen | 1 | 1997 | 963 | 0.030 |
Why?
|
| Cohort Studies | 6 | 2019 | 41649 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 1998 | 1776 | 0.030 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2000 | 961 | 0.030 |
Why?
|
| Taxoids | 2 | 2006 | 665 | 0.020 |
Why?
|
| Glycoside Hydrolases | 1 | 1992 | 135 | 0.020 |
Why?
|
| Perineum | 2 | 2006 | 213 | 0.020 |
Why?
|
| Neurodegenerative Diseases | 1 | 2001 | 1087 | 0.020 |
Why?
|
| Cyclophosphamide | 4 | 2004 | 2228 | 0.020 |
Why?
|
| Quantitative Trait Loci | 1 | 2020 | 2140 | 0.020 |
Why?
|
| Porphyrins | 1 | 2014 | 351 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2019 | 1774 | 0.020 |
Why?
|
| Proto-Oncogenes | 1 | 1993 | 320 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 3 | 2002 | 1679 | 0.020 |
Why?
|
| Genes, Reporter | 2 | 2011 | 1524 | 0.020 |
Why?
|
| Patient Selection | 2 | 2001 | 4255 | 0.020 |
Why?
|
| Receptors, Nerve Growth Factor | 1 | 1993 | 200 | 0.020 |
Why?
|
| Cisplatin | 4 | 2006 | 1658 | 0.020 |
Why?
|
| Hospitals | 1 | 2005 | 3888 | 0.020 |
Why?
|
| Prostate | 1 | 2000 | 1755 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2020 | 2920 | 0.020 |
Why?
|
| Cross-Sectional Studies | 3 | 2014 | 26318 | 0.020 |
Why?
|
| Antifungal Agents | 1 | 1997 | 769 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2015 | 1644 | 0.020 |
Why?
|
| DNA Repair | 3 | 2007 | 2048 | 0.020 |
Why?
|
| Cause of Death | 2 | 2003 | 3708 | 0.020 |
Why?
|
| Recurrence | 6 | 2006 | 8501 | 0.020 |
Why?
|
| Crosses, Genetic | 2 | 2003 | 752 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2005 | 7838 | 0.020 |
Why?
|
| Microinjections | 1 | 1992 | 320 | 0.020 |
Why?
|
| Interferon-gamma | 3 | 2008 | 3160 | 0.020 |
Why?
|
| Rats | 1 | 2008 | 23707 | 0.020 |
Why?
|
| Postoperative Care | 1 | 1998 | 1470 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 1992 | 285 | 0.020 |
Why?
|
| Learning | 2 | 2016 | 1755 | 0.020 |
Why?
|
| 3T3 Cells | 2 | 2003 | 1081 | 0.020 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1992 | 705 | 0.020 |
Why?
|
| Eating | 1 | 2018 | 1540 | 0.020 |
Why?
|
| Gallium Radioisotopes | 1 | 1991 | 195 | 0.020 |
Why?
|
| Osteopontin | 2 | 2003 | 304 | 0.020 |
Why?
|
| Radiation Injuries | 1 | 1998 | 1181 | 0.020 |
Why?
|
| Base Pairing | 1 | 2011 | 139 | 0.020 |
Why?
|
| Protein Transport | 1 | 2016 | 1939 | 0.020 |
Why?
|
| Aftercare | 1 | 1997 | 911 | 0.020 |
Why?
|
| Cell Survival | 4 | 2004 | 5747 | 0.020 |
Why?
|
| Intraoperative Period | 2 | 2005 | 508 | 0.020 |
Why?
|
| Thyroid Neoplasms | 1 | 2004 | 2371 | 0.020 |
Why?
|
| Blotting, Northern | 2 | 2002 | 1546 | 0.020 |
Why?
|
| Radiation, Ionizing | 1 | 2011 | 249 | 0.020 |
Why?
|
| Whole-Body Irradiation | 1 | 2011 | 438 | 0.020 |
Why?
|
| Endometrial Neoplasms | 1 | 1999 | 1378 | 0.020 |
Why?
|
| Ultrasonography | 2 | 2000 | 5993 | 0.020 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 2 | 2002 | 63 | 0.020 |
Why?
|
| Skin | 2 | 2008 | 4489 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 2 | 2004 | 1701 | 0.020 |
Why?
|
| Leukocyte Count | 2 | 2006 | 1602 | 0.020 |
Why?
|
| Oncolytic Viruses | 1 | 2014 | 344 | 0.020 |
Why?
|
| Stomach Neoplasms | 1 | 2000 | 1471 | 0.020 |
Why?
|
| Delayed-Action Preparations | 1 | 1993 | 967 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 1992 | 640 | 0.020 |
Why?
|
| Actuarial Analysis | 2 | 2004 | 366 | 0.020 |
Why?
|
| Ultrasonography, Interventional | 1 | 1998 | 1531 | 0.020 |
Why?
|
| Incidence | 4 | 2006 | 21480 | 0.020 |
Why?
|
| Glycosylation | 1 | 1992 | 1100 | 0.020 |
Why?
|
| Drosophila Proteins | 1 | 1999 | 1697 | 0.020 |
Why?
|
| Quality Control | 2 | 2003 | 837 | 0.020 |
Why?
|
| Radiography | 2 | 2014 | 6919 | 0.020 |
Why?
|
| Remission Induction | 5 | 1994 | 2411 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2001 | 2339 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2015 | 1673 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2015 | 1966 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2016 | 2739 | 0.020 |
Why?
|
| Actins | 1 | 2016 | 2056 | 0.020 |
Why?
|
| Lung | 1 | 2007 | 10033 | 0.020 |
Why?
|
| Neoplasms, Second Primary | 1 | 1997 | 1050 | 0.020 |
Why?
|
| Osteosarcoma | 1 | 1995 | 909 | 0.020 |
Why?
|
| Dacarbazine | 3 | 1998 | 552 | 0.020 |
Why?
|
| Mediastinal Neoplasms | 1 | 1991 | 403 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 1992 | 1752 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2019 | 2921 | 0.020 |
Why?
|
| Histone Acetyltransferases | 1 | 2010 | 332 | 0.020 |
Why?
|
| Antigens, CD | 2 | 2006 | 4025 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2006 | 8923 | 0.020 |
Why?
|
| Neutrophils | 1 | 2001 | 3776 | 0.020 |
Why?
|
| Regulatory Elements, Transcriptional | 1 | 2009 | 184 | 0.020 |
Why?
|
| Erythroblasts | 1 | 2008 | 142 | 0.020 |
Why?
|
| Diagnosis, Differential | 3 | 2015 | 12976 | 0.020 |
Why?
|
| Cation Transport Proteins | 1 | 2011 | 325 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2014 | 1885 | 0.020 |
Why?
|
| Oncolytic Virotherapy | 1 | 2014 | 520 | 0.020 |
Why?
|
| Hemoglobinopathies | 1 | 2008 | 101 | 0.020 |
Why?
|
| Mi-2 Nucleosome Remodeling and Deacetylase Complex | 1 | 2008 | 116 | 0.020 |
Why?
|
| Body Mass Index | 2 | 2005 | 13039 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2018 | 2334 | 0.020 |
Why?
|
| Pancreatic Neoplasms | 1 | 2006 | 5444 | 0.020 |
Why?
|
| Guidelines as Topic | 2 | 2005 | 1394 | 0.020 |
Why?
|
| Statistics, Nonparametric | 2 | 2005 | 2844 | 0.020 |
Why?
|
| Acetylation | 1 | 2010 | 1053 | 0.020 |
Why?
|
| Adiposity | 1 | 2018 | 1890 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2001 | 6255 | 0.020 |
Why?
|
| Antibodies | 1 | 1995 | 2417 | 0.020 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 2 | 1 | 2007 | 42 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 1999 | 6493 | 0.020 |
Why?
|
| RNA, Messenger | 4 | 2008 | 12768 | 0.020 |
Why?
|
| Disease Outbreaks | 1 | 1997 | 1759 | 0.020 |
Why?
|
| 1-Carboxyglutamic Acid | 1 | 1987 | 19 | 0.020 |
Why?
|
| Diarrhea | 1 | 2014 | 1316 | 0.020 |
Why?
|
| Guanine | 1 | 2008 | 282 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 1992 | 1385 | 0.020 |
Why?
|
| Glutamates | 1 | 2008 | 384 | 0.020 |
Why?
|
| DNA, Neoplasm | 3 | 2002 | 1742 | 0.020 |
Why?
|
| DNA Fragmentation | 1 | 2007 | 238 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 1998 | 2778 | 0.020 |
Why?
|
| Factor IX | 1 | 1987 | 76 | 0.020 |
Why?
|
| DNA Adducts | 1 | 2007 | 94 | 0.020 |
Why?
|
| Metaplasia | 1 | 2007 | 326 | 0.020 |
Why?
|
| Coloring Agents | 2 | 2001 | 564 | 0.020 |
Why?
|
| Anthropometry | 2 | 2002 | 1338 | 0.020 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2006 | 175 | 0.020 |
Why?
|
| Bystander Effect | 1 | 2006 | 90 | 0.020 |
Why?
|
| Happiness | 1 | 1988 | 173 | 0.020 |
Why?
|
| Contrast Media | 2 | 2014 | 5329 | 0.020 |
Why?
|
| Attention | 1 | 2016 | 2419 | 0.020 |
Why?
|
| Life Style | 1 | 2018 | 3926 | 0.020 |
Why?
|
| Virus Replication | 1 | 2014 | 2447 | 0.020 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2006 | 218 | 0.020 |
Why?
|
| Retinoblastoma-Binding Protein 4 | 1 | 2005 | 12 | 0.020 |
Why?
|
| RNA Polymerase II | 1 | 2010 | 549 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2010 | 682 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2001 | 4863 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2008 | 745 | 0.020 |
Why?
|
| United States | 3 | 2016 | 72903 | 0.020 |
Why?
|
| Genes, DCC | 1 | 2005 | 10 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 1997 | 4493 | 0.020 |
Why?
|
| Attitude to Health | 2 | 2005 | 2020 | 0.020 |
Why?
|
| Polyvinyl Alcohol | 1 | 2006 | 74 | 0.020 |
Why?
|
| Drug Industry | 2 | 2003 | 791 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2009 | 1886 | 0.020 |
Why?
|
| Multigene Family | 1 | 2008 | 1080 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2016 | 3139 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2006 | 295 | 0.020 |
Why?
|
| Registries | 1 | 2021 | 8297 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2011 | 2060 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 3421 | 0.020 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2005 | 110 | 0.020 |
Why?
|
| DNA Fingerprinting | 1 | 2005 | 114 | 0.010 |
Why?
|
| Early Growth Response Transcription Factors | 1 | 2005 | 32 | 0.010 |
Why?
|
| Pregnancy Outcome | 1 | 2016 | 2966 | 0.010 |
Why?
|
| Administration, Oral | 2 | 2004 | 4015 | 0.010 |
Why?
|
| Kinetics | 1 | 1992 | 6274 | 0.010 |
Why?
|
| Procarbazine | 2 | 1997 | 172 | 0.010 |
Why?
|
| Mechlorethamine | 2 | 1997 | 129 | 0.010 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2006 | 202 | 0.010 |
Why?
|
| Pregnancy | 3 | 2016 | 30260 | 0.010 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2019 | 3251 | 0.010 |
Why?
|
| Nucleotides | 1 | 2007 | 451 | 0.010 |
Why?
|
| Terminology as Topic | 1 | 1992 | 1534 | 0.010 |
Why?
|
| History, 18th Century | 1 | 2005 | 206 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2006 | 610 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2004 | 2453 | 0.010 |
Why?
|
| Depression | 1 | 2004 | 8237 | 0.010 |
Why?
|
| Decision Trees | 1 | 2006 | 509 | 0.010 |
Why?
|
| Cell Movement | 1 | 2016 | 5194 | 0.010 |
Why?
|
| Eye Neoplasms | 1 | 2006 | 304 | 0.010 |
Why?
|
| Karyotyping | 1 | 2006 | 1178 | 0.010 |
Why?
|
| Cerebrovascular Circulation | 1 | 2014 | 2674 | 0.010 |
Why?
|
| bcl-X Protein | 1 | 2006 | 414 | 0.010 |
Why?
|
| Smad4 Protein | 1 | 2005 | 193 | 0.010 |
Why?
|
| Flow Cytometry | 3 | 2002 | 5881 | 0.010 |
Why?
|
| Farnesyltranstransferase | 1 | 2004 | 70 | 0.010 |
Why?
|
| Tissue Array Analysis | 1 | 2005 | 545 | 0.010 |
Why?
|
| Protein Prenylation | 1 | 2004 | 69 | 0.010 |
Why?
|
| Nutritional Status | 2 | 2003 | 1620 | 0.010 |
Why?
|
| Tomography, Spiral Computed | 1 | 2005 | 273 | 0.010 |
Why?
|
| Bleomycin | 2 | 1997 | 491 | 0.010 |
Why?
|
| Paris | 1 | 2003 | 40 | 0.010 |
Why?
|
| HSP40 Heat-Shock Proteins | 1 | 2004 | 86 | 0.010 |
Why?
|
| Sigmoidoscopy | 1 | 2004 | 150 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2016 | 7123 | 0.010 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2005 | 341 | 0.010 |
Why?
|
| Control Groups | 1 | 2003 | 106 | 0.010 |
Why?
|
| Personal Satisfaction | 1 | 1988 | 641 | 0.010 |
Why?
|
| Urinary Catheterization | 1 | 2004 | 195 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 1 | 1991 | 2729 | 0.010 |
Why?
|
| Urethane | 1 | 2002 | 37 | 0.010 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2004 | 269 | 0.010 |
Why?
|
| Genetic Testing | 2 | 2007 | 3595 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2007 | 3737 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 2011 | 1944 | 0.010 |
Why?
|
| Autoantibodies | 1 | 1991 | 2113 | 0.010 |
Why?
|
| Blotting, Western | 2 | 2002 | 5020 | 0.010 |
Why?
|
| Body Image | 1 | 1988 | 644 | 0.010 |
Why?
|
| Microspheres | 1 | 2006 | 773 | 0.010 |
Why?
|
| Therapies, Investigational | 1 | 2003 | 110 | 0.010 |
Why?
|
| Protein Precursors | 1 | 1987 | 1134 | 0.010 |
Why?
|
| Models, Molecular | 1 | 1992 | 5379 | 0.010 |
Why?
|
| Phenylhydrazines | 1 | 2002 | 28 | 0.010 |
Why?
|
| Leukopoiesis | 1 | 2002 | 54 | 0.010 |
Why?
|
| Hepatectomy | 1 | 2006 | 589 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2004 | 858 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2004 | 474 | 0.010 |
Why?
|
| Injections, Intradermal | 1 | 2002 | 116 | 0.010 |
Why?
|
| Rosaniline Dyes | 1 | 2002 | 52 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2004 | 479 | 0.010 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2005 | 506 | 0.010 |
Why?
|
| Pluripotent Stem Cells | 1 | 2009 | 807 | 0.010 |
Why?
|
| Biological Assay | 1 | 2005 | 627 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2002 | 314 | 0.010 |
Why?
|
| Loss of Heterozygosity | 1 | 2004 | 663 | 0.010 |
Why?
|
| Genetic Counseling | 1 | 2005 | 634 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2009 | 2194 | 0.010 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2002 | 120 | 0.010 |
Why?
|
| Interleukin-5 | 1 | 2002 | 268 | 0.010 |
Why?
|
| Hematoxylin | 1 | 2001 | 61 | 0.010 |
Why?
|
| Alcohol Oxidoreductases | 1 | 2002 | 164 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 1998 | 14751 | 0.010 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2001 | 70 | 0.010 |
Why?
|
| Molecular Biology | 1 | 2005 | 574 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2008 | 2927 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2002 | 812 | 0.010 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2016 | 3719 | 0.010 |
Why?
|
| Vaginal Smears | 1 | 2004 | 513 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2020 | 12807 | 0.010 |
Why?
|
| Reminder Systems | 1 | 2004 | 388 | 0.010 |
Why?
|
| Cytodiagnosis | 1 | 2005 | 453 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2016 | 9347 | 0.010 |
Why?
|
| New York City | 1 | 2003 | 733 | 0.010 |
Why?
|
| Linear Models | 1 | 2011 | 5876 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2008 | 1857 | 0.010 |
Why?
|
| Zinc | 1 | 2005 | 675 | 0.010 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2005 | 878 | 0.010 |
Why?
|
| Safety | 1 | 2005 | 1157 | 0.010 |
Why?
|
| Hematocrit | 1 | 2002 | 621 | 0.010 |
Why?
|
| Decision Making | 2 | 2005 | 3965 | 0.010 |
Why?
|
| Dipyridamole | 1 | 1980 | 137 | 0.010 |
Why?
|
| Lymphography | 1 | 2001 | 189 | 0.010 |
Why?
|
| Amenorrhea | 1 | 2004 | 470 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2016 | 8067 | 0.010 |
Why?
|
| Interpersonal Relations | 1 | 1988 | 1432 | 0.010 |
Why?
|
| COS Cells | 1 | 2002 | 1136 | 0.010 |
Why?
|
| Histones | 1 | 2010 | 2584 | 0.010 |
Why?
|
| Thyroxine | 1 | 2004 | 672 | 0.010 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2004 | 488 | 0.010 |
Why?
|
| Cross-Cultural Comparison | 1 | 2003 | 634 | 0.010 |
Why?
|
| Angiography | 1 | 2005 | 1581 | 0.010 |
Why?
|
| Prednisone | 2 | 1997 | 1565 | 0.010 |
Why?
|
| Heat-Shock Proteins | 1 | 2004 | 791 | 0.010 |
Why?
|
| Caspase 9 | 1 | 2000 | 184 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2002 | 462 | 0.010 |
Why?
|
| Risk Assessment | 3 | 2005 | 24282 | 0.010 |
Why?
|
| Sleep Stages | 1 | 2004 | 698 | 0.010 |
Why?
|
| Transcription Factor 7-Like 1 Protein | 1 | 1999 | 23 | 0.010 |
Why?
|
| Janus Kinase 2 | 1 | 2003 | 562 | 0.010 |
Why?
|
| Melanoma, Experimental | 1 | 2003 | 558 | 0.010 |
Why?
|
| Mammography | 2 | 2004 | 2423 | 0.010 |
Why?
|
| Caspase 8 | 1 | 2000 | 198 | 0.010 |
Why?
|
| Amino Acid Motifs | 1 | 2002 | 924 | 0.010 |
Why?
|
| Cystectomy | 1 | 2004 | 604 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 6499 | 0.010 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2005 | 1119 | 0.010 |
Why?
|
| Metalloproteins | 1 | 1999 | 98 | 0.010 |
Why?
|
| Papillomaviridae | 1 | 2005 | 1141 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2004 | 1240 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 1987 | 1957 | 0.010 |
Why?
|
| TCF Transcription Factors | 1 | 1999 | 137 | 0.010 |
Why?
|
| Conserved Sequence | 1 | 2002 | 1160 | 0.010 |
Why?
|
| Immunotherapy | 2 | 2006 | 4752 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2013 | 4424 | 0.010 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2010 | 1883 | 0.010 |
Why?
|
| Vulnerable Populations | 1 | 2004 | 718 | 0.010 |
Why?
|
| Transgenes | 1 | 2002 | 1015 | 0.010 |
Why?
|
| ras Proteins | 1 | 2004 | 1053 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2008 | 2210 | 0.010 |
Why?
|
| Deoxyribonuclease I | 1 | 1999 | 228 | 0.010 |
Why?
|
| Platelet Count | 1 | 2001 | 782 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2003 | 1965 | 0.010 |
Why?
|
| DNA, Viral | 1 | 2005 | 2199 | 0.010 |
Why?
|
| Embryonic and Fetal Development | 1 | 1999 | 419 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1999 | 1056 | 0.010 |
Why?
|
| Blood Pressure | 1 | 1993 | 8532 | 0.010 |
Why?
|
| Dactinomycin | 1 | 1998 | 304 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2000 | 731 | 0.010 |
Why?
|
| Peritoneal Neoplasms | 1 | 2004 | 703 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2002 | 2745 | 0.010 |
Why?
|
| Obesity | 1 | 2000 | 13076 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2005 | 3624 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2002 | 1740 | 0.010 |
Why?
|
| Heart | 1 | 2011 | 4414 | 0.010 |
Why?
|
| Biophysical Phenomena | 1 | 1998 | 318 | 0.010 |
Why?
|
| Vertebrates | 1 | 1999 | 227 | 0.010 |
Why?
|
| Cyclin D1 | 1 | 1999 | 449 | 0.010 |
Why?
|
| Teniposide | 1 | 1997 | 11 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2014 | 7851 | 0.010 |
Why?
|
| Intraoperative Care | 1 | 2001 | 760 | 0.010 |
Why?
|
| Hypnotics and Sedatives | 1 | 2005 | 1191 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2005 | 1995 | 0.010 |
Why?
|
| Fetal Heart | 1 | 1999 | 281 | 0.010 |
Why?
|
| Biophysics | 1 | 1998 | 375 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2002 | 1831 | 0.010 |
Why?
|
| Kidney | 1 | 1992 | 7066 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2004 | 1272 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2003 | 3432 | 0.010 |
Why?
|
| Colloids | 1 | 1997 | 122 | 0.010 |
Why?
|
| Methotrexate | 1 | 2004 | 1722 | 0.010 |
Why?
|
| Caspases | 1 | 2000 | 880 | 0.010 |
Why?
|
| Haplotypes | 1 | 2003 | 2728 | 0.010 |
Why?
|
| Adaptation, Psychological | 1 | 1988 | 2660 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 2004 | 2424 | 0.010 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2000 | 305 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2003 | 3618 | 0.010 |
Why?
|
| Fatigue | 1 | 2004 | 1549 | 0.010 |
Why?
|
| Clone Cells | 1 | 2000 | 1672 | 0.010 |
Why?
|
| Consumer Product Safety | 1 | 1997 | 121 | 0.010 |
Why?
|
| Education, Medical, Continuing | 1 | 2001 | 830 | 0.010 |
Why?
|
| Colonoscopy | 1 | 2004 | 1406 | 0.010 |
Why?
|
| MAP Kinase Signaling System | 1 | 2003 | 1490 | 0.010 |
Why?
|
| Necrosis | 1 | 2000 | 1617 | 0.010 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 1980 | 521 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1998 | 1377 | 0.010 |
Why?
|
| Skin Ulcer | 1 | 1997 | 130 | 0.010 |
Why?
|
| Dendritic Cells | 1 | 2006 | 2747 | 0.010 |
Why?
|
| Skin Pigmentation | 1 | 1997 | 279 | 0.010 |
Why?
|
| Stromal Cells | 1 | 2000 | 1329 | 0.010 |
Why?
|
| Epirubicin | 1 | 1994 | 82 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 1999 | 2171 | 0.010 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2003 | 3608 | 0.010 |
Why?
|
| Geriatric Assessment | 1 | 2002 | 1429 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 15880 | 0.010 |
Why?
|
| Hyperthermia, Induced | 1 | 1998 | 415 | 0.010 |
Why?
|
| Anti-Infective Agents | 1 | 2002 | 986 | 0.010 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 1999 | 698 | 0.010 |
Why?
|
| Sarcoma, Synovial | 1 | 1995 | 155 | 0.010 |
Why?
|
| Growth Substances | 1 | 1996 | 758 | 0.010 |
Why?
|
| RNA | 1 | 2003 | 2717 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 2003 | 2415 | 0.010 |
Why?
|
| Fibrosarcoma | 1 | 1995 | 313 | 0.010 |
Why?
|
| Immune Tolerance | 1 | 2002 | 2324 | 0.010 |
Why?
|
| Mammals | 1 | 1999 | 1125 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1998 | 2229 | 0.010 |
Why?
|
| Testosterone | 1 | 2004 | 2494 | 0.010 |
Why?
|
| Quality Assurance, Health Care | 1 | 2003 | 2172 | 0.010 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1997 | 679 | 0.010 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 1997 | 614 | 0.010 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 1999 | 1140 | 0.010 |
Why?
|
| Androgens | 1 | 2000 | 1279 | 0.010 |
Why?
|
| Catheter Ablation | 1 | 2006 | 2788 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2001 | 4137 | 0.010 |
Why?
|
| Peptide Mapping | 1 | 1992 | 259 | 0.010 |
Why?
|
| Drug Carriers | 1 | 1997 | 700 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2002 | 3404 | 0.010 |
Why?
|
| Disease Models, Animal | 2 | 2002 | 18293 | 0.010 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1993 | 412 | 0.010 |
Why?
|
| Mitral Valve | 1 | 1980 | 1476 | 0.010 |
Why?
|
| Heart Valve Prosthesis | 1 | 1980 | 1466 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2007 | 10429 | 0.010 |
Why?
|
| Podophyllotoxin | 1 | 1991 | 20 | 0.010 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2004 | 2176 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2002 | 5501 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1992 | 772 | 0.010 |
Why?
|
| Drosophila | 1 | 1999 | 1501 | 0.010 |
Why?
|
| Dietary Supplements | 1 | 2004 | 3425 | 0.010 |
Why?
|
| Aortic Valve | 1 | 1980 | 1968 | 0.010 |
Why?
|
| Health Education | 1 | 1997 | 1060 | 0.010 |
Why?
|
| Colon | 1 | 1998 | 1795 | 0.010 |
Why?
|
| Nerve Growth Factors | 1 | 1993 | 565 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 2005 | 4533 | 0.010 |
Why?
|
| Phantoms, Imaging | 1 | 1998 | 2475 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2002 | 3050 | 0.010 |
Why?
|
| Analgesics, Opioid | 1 | 2005 | 3835 | 0.000 |
Why?
|
| Neutropenia | 1 | 1994 | 893 | 0.000 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1992 | 1526 | 0.000 |
Why?
|
| Psychometrics | 1 | 1998 | 3062 | 0.000 |
Why?
|
| Mental Health | 1 | 2003 | 3278 | 0.000 |
Why?
|
| Comorbidity | 1 | 2003 | 10563 | 0.000 |
Why?
|
| Lysine | 1 | 1992 | 991 | 0.000 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1999 | 2674 | 0.000 |
Why?
|
| Case-Control Studies | 1 | 2005 | 22223 | 0.000 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1991 | 2476 | 0.000 |
Why?
|
| Palliative Care | 1 | 2002 | 3645 | 0.000 |
Why?
|
| Mitosis | 1 | 1992 | 1173 | 0.000 |
Why?
|
| Drug Administration Schedule | 1 | 1994 | 4850 | 0.000 |
Why?
|
| Transplantation, Autologous | 1 | 1991 | 2120 | 0.000 |
Why?
|
| Education, Medical | 1 | 1997 | 1746 | 0.000 |
Why?
|
| Abdomen | 1 | 1991 | 1134 | 0.000 |
Why?
|
| Vitamin K | 1 | 1987 | 312 | 0.000 |
Why?
|
| Proteins | 1 | 1999 | 5995 | 0.000 |
Why?
|
| Public Health | 1 | 1997 | 2680 | 0.000 |
Why?
|
| Peptides | 1 | 1987 | 4331 | 0.000 |
Why?
|
| Thromboembolism | 1 | 1980 | 1003 | 0.000 |
Why?
|
| Delivery, Obstetric | 1 | 1980 | 946 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1991 | 20659 | 0.000 |
Why?
|